Hydroxychloroquine

Generic Name
Hydroxychloroquine
Brand Names
Plaquenil, Sovuna
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3O
CAS Number
118-42-3
Unique Ingredient Identifier
4QWG6N8QKH
Background

Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...

Indication

Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

Associated Conditions
Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
Associated Therapies
-
Clinical Trials
Related News

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II

First Posted Date
2012-07-25
Last Posted Date
2022-11-21
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
32
Registration Number
NCT01649947
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Robert Wood Johnson University Hospital at Hamilton, Hamilton, New Jersey, United States

A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

First Posted Date
2012-05-21
Last Posted Date
2018-05-03
Lead Sponsor
University College, London
Target Recruit Count
54
Registration Number
NCT01602588
Locations
🇬🇧

Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

🇬🇧

St James's University Hospital, Leeds, West Yorkshire, United Kingdom

🇬🇧

Ninewells Hospital, Dundee, United Kingdom

and more 12 locations

Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome

First Posted Date
2012-05-17
Last Posted Date
2013-10-17
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
39
Registration Number
NCT01601028
Locations
🇰🇷

Seoul National Unversity Hospital, Seoul, Korea, Republic of

Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda

First Posted Date
2012-04-09
Last Posted Date
2023-02-17
Lead Sponsor
The University of Texas Medical Branch, Galveston
Target Recruit Count
48
Registration Number
NCT01573754
Locations
🇺🇸

University of Texas Medical Branch, Galveston, Texas, United States

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

First Posted Date
2012-03-12
Last Posted Date
2020-01-02
Lead Sponsor
Leonard Appleman
Target Recruit Count
30
Registration Number
NCT01550367
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, United States

🇺🇸

The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

Loyola University Chicago, Maywood, Illinois, United States

and more 4 locations

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

First Posted Date
2012-02-23
Last Posted Date
2014-11-19
Lead Sponsor
University of Arkansas
Target Recruit Count
8
Registration Number
NCT01537315
Locations
🇺🇸

University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

🇺🇸

Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

First Posted Date
2012-01-13
Last Posted Date
2020-04-24
Lead Sponsor
Abramson Cancer Center at Penn Medicine
Target Recruit Count
40
Registration Number
NCT01510119
Locations
🇺🇸

University of Pittsburgh, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

🇺🇸

University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States

🇺🇸

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Treatment of Muscle Cramps in Patients With Liver Cirrhosis

Early Phase 1
Completed
Conditions
Muscle Cramps
Liver Cirrhosis
Interventions
Drug: Hydroxychloroquine
First Posted Date
2011-12-20
Last Posted Date
2023-05-03
Lead Sponsor
Mayo Clinic
Target Recruit Count
3
Registration Number
NCT01495403
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer

First Posted Date
2011-12-16
Last Posted Date
2021-02-02
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
50
Registration Number
NCT01494155
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

First Posted Date
2011-11-28
Last Posted Date
2024-03-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
62
Registration Number
NCT01480154
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy